GSVRX
Price
$16.41
Change
+$0.08 (+0.49%)
Updated
Jun 9 closing price
Net Assets
457.1M
RMFEX
Price
$62.62
Change
+$0.38 (+0.61%)
Updated
Jun 9 closing price
Net Assets
116.64B
Interact to see
Advertisement

GSVRX vs RMFEX

Header iconGSVRX vs RMFEX Comparison
Open Charts GSVRX vs RMFEXBanner chart's image
GSVRX vs RMFEX Comparison Chart in %
View a ticker or compare two or three
VS
GSVRX vs. RMFEX commentary
Jun 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSVRX is a Buy and RMFEX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFEX has more cash in the bank: 117B vs. GSVRX (457M). RMFEX pays higher dividends than GSVRX: RMFEX (1.45) vs GSVRX (0.43). GSVRX was incepted earlier than RMFEX: GSVRX (19 years) vs RMFEX (24 years). GSVRX (1.49) is less costly to investors than RMFEX (0.62). GSVRX is a more actively managed with annual turnover of: 74.00 vs. RMFEX (30.00). GSVRX has a lower initial minimum investment than RMFEX: GSVRX (0) vs RMFEX (250). RMFEX annual gain was more profitable for investors over the last year : 9.69 vs. GSVRX (7.60). RMFEX return over 5 years is better than : 35.70 vs. GSVRX (0.93).
GSVRXRMFEXGSVRX / RMFEX
Total Expense Ratio1.250.62202%
Annual Report Gross Expense Ratio1.490.62240%
Fund Existence19 years24 years-
Gain YTD13.0896.156213%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets457M117B0%
Annual Yield % from dividends0.431.4530%
Returns for 1 year7.609.6978%
Returns for 3 years19.3735.7054%
Returns for 5 years0.9335.703%
Returns for 10 years18.2499.3218%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBFG22.890.65
+2.92%
SB Financial Group
KRO6.530.02
+0.31%
Kronos Worldwide
BOX26.54-0.01
-0.04%
BOX
MTSI358.72-3.14
-0.87%
MACOM Technology Solutions Holdings
BOLT4.62-0.10
-2.12%
Bolt Biotherapeutics Inc